Abstract Non-viral transfection is a promising technique that could be used to increase the therapeutic potential of stem cells. The purpose of this study was to explore practical culture parameters of relevance in potential human mesenchymal stem cell (hMSC) clinical and tissue engineering applications, including type of polycationic transfection reagent, N/P ratio and dose of polycation/pDNA polyplexes, cell passage number, cell density and cell proliferation. The non-viral transfection efficiency was significantly influenced by N/P ratio, polyplex dose, cell density and cell passage number. hMSC culture conditions that inhibited cell division also decreased transfection efficiency, suggesting that strategies to promote hMSC proliferation may be useful to enhance transfection efficiency in future tissue engineering studies. Non-viral transfection treatments influenced hMSC phenotype, including the expression level of the hMSC marker CD105 and the ability of hMSCs to differentiate down the osteogenic and adipogenic lineages. The parameters found here to promote hMSC transfection efficiency, minimize toxicity and influence hMSC phenotype may be instructive in future non-viral transfection studies and tissue engineering applications.
Introduction
Non-viral transfection has become an important approach in tissue engineering applications, as it allows for forced overexpression of specific proteins that influence cell behavior. Protein overexpression is particularly important in controlling stem cell processes and products. For example, stem cells have been transfected to influence cell survival (Jo et al. 2007; Song et al. 2005) , differentiation (Dragoo et al. 2003) , telomerase activity (Poh et al. 2005) , therapeutic protein production (Wang et al. 2009 ) and new tissue formation (Huang et al. 2005; Madry et al. 2002; Shea et al. 1999) . Therefore, the non-viral transfection of stem cells could enable new approaches in tissue engineering to meet key therapeutic needs.
Human mesenchymal stem cells (hMSCs) may be useful targets for transfection, as they differentiate into multiple clinically relevant cell types including bone, fat and cartilage (Pittenger et al. 1999) and their lineage-specific differentiation of cells can be strongly influenced by cellular gene expression (Friedenstein et al. 1970; Pittenger et al. 1999) . For example, forced overexpression of the cytokines bone morphogenetic protein-2 (Hosseinkhani et al. 2006) or insulin-like growth factor-1 (Koch et al. 2005 ) via DNA delivery has been shown to induce osteogenic differentiation of hMSCs. In addition, Garcia and coworkers have shown that forced overexpression of the regulatory gene Cbfa1/Runx2 promotes osteogenic differentiation of MSCs (Byers and Garcia 2004) . Forced overexpression of the transcription factor Sox9 has also been used to promote chondrogenesis by MSCs (Tsuchiya et al. 2003) . However, in each of these applications the potential utility of non-viral transfection approaches is critically dependent on MSC transfection efficiency, as well as practical issues such as cost and scalability.
A variety of approaches can be used to modulate the nonviral transfection efficiency of hMSCs. For example, 25 kDa branched polyethyleneimine (PEI), Lipofectamine 2000, poly-l-lysine-palmitic acid, poly-l-lysine, cationized dextran, Fugene and Effectene have been explored as polycationic transfection reagents in hMSC culture (Baksh et al. 2007; Clements et al. 2006; Clements et al. 2007a; Farrell et al. 2007; Jo et al. 2007) . A common theme in these approaches is the use of polycationic vectors to condense plasmid DNA (pDNA) into "polyplexes", neutralize DNA charge and promote endosomal escape into the cytoplasm. In these various studies, the transfection efficiency of hMSCs -defined as the number of cells expressing a fluorescent reporter divided by the total number of cells -is typically less than 20% unless there are multiple rounds of transfection or other additives, such as chloroquine (Clements et al. 2007b) , are used to increase transfection efficiency. In addition, it is likely that the efficiency of DNA delivery to cells is highly contextdependent and cell culture parameters such as cell density, cell proliferation rate and media components may strongly influence non-viral DNA uptake and expression (Audouy et al. 2000) .
The choice of non-viral transfection parameters for tissue engineering applications must be both efficient and practical to be clinically relevant. Effective non-viral transfection in hMSC-based biotechnology applications, such as largescale cell production for drug screening or cell therapy, will probably require reagents and culture conditions that are low-cost and scalable. Currently, only PEI-and calcium phosphate-mediated transfection are considered scalable and cost-effective for liter-scale cultures (Durocher et al. 2002) . For example, PEI has been used to transfect mammalian cells in 20-liter WAVE bioreactors (Haldankar et al. 2006) , 50-l orbital shaker bioreactors (Stettler et al. 2007 ) and 100-l stirred tank bioreactors (Tuvesson et al. 2008) . Also, PEI costs 4,000-5,000 times less per liter than several commercially available transfection reagents (Morrow 2008) . PEI has been used in clinical trials, which suggests that it could be used for clinical applications as well as other biotechnology applications (Anwer et al. 2010 ). Together, these previous studies suggest that PEI is one of the few practical non-viral vectors currently available for large-scale transfections for tissue engineering applications.
Optimized cell-culture conditions will be critical for the success of any hMSC-based approach in which hMSC proliferation, transfection efficiency and multipotency must be tightly regulated. Therefore, this study was designed to explore standard cell-culture parameters that may influence hMSC transfection, with a particular emphasis on PEI as a transfection reagent for the practical reasons outlined in the previous paragraph. The particular focus is on parameters that can be easily adapted for tissue engineering applications, including the cell density, the cell passage number, the type of non-viral vector (60 kDa branched PEI, Superfect, and JetPEI), the N/P ratio (the ratio of primary amines on PEI to phosphate groups on pDNA) and dose of PEI:pDNA polyplexes. Results indicate that each parameter studied influences hMSC transfection and viability. We also observed differences in the multipotency of hMSCs after transfection in preliminary experiments using immunostaining for a common hMSC cell surface marker, CD105 and by observing their differentiation down the osteogenic and adipogenic lineages in vitro.
Materials and methods
Cell culture hMSCs were purchased from Cambrex (East Rutherford, NJ, USA) and grown in basal media [Dulbecco's modified Eagle Medium (Mediatech Inc, Herdon, VA, USA) supplemented with 1% penicillin/streptomycin (Gibco, Carlsbad, CA, USA) and 10% Mesenchymal Stem Cell Qualified Fetal Bovine Serum (Invitrogen, Carlsbad, CA, USA)]. Twenty-four hours prior to transfection hMSCs were passaged using standard cell-culture techniques and 5,000 cells/cm 2 (unless otherwise noted) were plated in 1 ml of media in wells of a 24-well plate (BD Biosciences, San Jose, CA, USA). Four cell-culture wells per condition were prepared, treated and analyzed. The values on the graphs represent means and standard deviations. Student's t-tests were used to assess differences between individual data points and comparisons with p<0.05 were considered statistically significant. Transfection methods PEI stock solutions (Sigma, St. Louis, MO, USA) were formulated by diluting PEI in ultrapure H 2 O (18MΩ resistance) to a final concentration of 10 μM unless otherwise indicated. The pH of the solution was adjusted to 7.4 by adding 2 N HCl (Fisher Scientific, Fairlawn, NJ, USA). The solution was filtered through a 0.22 μM pore size PTFE Membrane (Millipore, Bedford, MA, USA). Superfect (Qiagen) and JetPEI (Polyplus Transfection, New York, NY, USA) were used per manufacturer's recommendations with a dose of 1 μg/well plasmid DNA (pDNA). The pDNA used throughout this study was pEGFP-N1 (Clontech, Mountain View, CA, USA), which was acquired from the Waisman Clinical Biomanufacturing Facility (Madison, WI, USA). PEI and pDNA were added to separate containers of 150 mM sterile NaCl and allowed to equilibrate for 5 minutes. The N/P ratios were calculated using the technique outlined by Boussif and colleagues (1ul of 10 μM 60 kDa PEI stock solution010 nmol primary amine/1ug of pDNA03 nmol phosphate) (Boussif et al. 1995 ). The polyplex solutions were then pipetted gently 5 times and centrifuged for 1 second. The pDNA and transfection reagents were incubated for 25 minutes to allow for complexation to occur. During this incubation, hMSCs were washed with phosphate-buffered saline (PBS) and fresh serum-containing media were added. After the incubation period, the pDNA:transfection agent polyplexes were added to the cell culture media.
hMSC transfection efficiency and cytotoxicity Transfected cells were observed at predetermined times on an Olympus IX51 epifluorescent microscope (Olympus, Tokyo, Japan). Digital micrographs were captured using a Hamamatzu C4742-05 CCD Camera (Hirakuchi, Hamakita-City, Japan) and processed using Simple PCI software (Hamatzu, Hamakita-City, Japan). The transfection efficiency of a treatment was quantified using a method that involved counting the number of GFP + cells on the cell culture substrate and dividing by the total number of cells measured using the CellTiter-Blue Assay (Promega, Madison, WI, USA) on a Synergy HT plate reader (Biotek, Santa Barbara, CA, USA). The CellTiter-Blue Assay works on the principle that metabolically active cells convert a non-fluorescent dye, resazurin, into a fluorescent end product resorufin that can be measured using a fluorimeter. Transfected cell viability was also evaluated using the CellTiter-Blue Assay (Promega).
Characterizing the influence of hMSC division on transfection
Experiments to characterize the influence of hMSC division on transfection involved inhibiting division using either a soluble inhibitor (mitomycin C, Sigma, Saint Louis, MO, USA) or gamma radiation. First, a preliminary experiment was performed to determine the appropriate dose of mitomycin C needed to inhibit division but not substantially decrease hMSC viability. The mitomycin C dose was optimized by plating 3,000 hMSCs and then treating them with 0-100 μg/ml mitomycin C for 0-6 hours. After treatment with mitomycin C or treatment with 6000 rad gamma radiation (Cs-137 source), transfection procedures were conducted as previously described.
Immunostaining
The CD105 expression of hMSCs was evaluated using a mouse monoclonal CD105 antibody conjugated to Phycoerythrin (Abcam, Cambridge, MA, USA) using standard immunocytochemistry techniques. Vectorshield DAPI (Vector Labs, Burlingame, CA, USA) was used to stain DNA using manufacturer's recommendations. CD105 antibodyPhycoerythrin fluorescence intensity was quantified by measuring fluorescence emission of >50 cells per culture condition with ImageJ software (Freeware, NIH, Bethesda, MD, USA).
Differentiation protocols
Osteogenic differentiation: hMSCs were grown to different densities (30% confluency was considered low density, 70% confluency was considered high density) in hMSC growth media. After the desired density was reached, the hMSCs were washed with osteogenic induction media [basal media+ 0.1μM dexamethasone, 10 mM β-glycerol phosphate and 50μM ascorbic acid 2-phosphate (Cambrex, East Rutherford, NJ, USA) with 2 mM L-glutamine (Hyclone, Logan, UT, USA) and 10% MCGS serum (Cambrex)]. The osteogenic induction medium was replaced every 3 days. Alkaline phosphatase staining was performed using manufacturer's instructions (Genehunter Corporation, Nashville, TN, USA) 7 days post osteogenic induction and alizarin red staining (Acros, Geel, Belgium) was performed using standard cytochemistry techniques.
Adipogenic differentiation: hMSCs were grown to different densities (30% confluency was considered low density, 100% confluency was considered high density) in hMSC basal media that was then replaced with adipogenic induction media [basal media+1 μM dexamethasone (MP Biomedicals, Solon, OH, USA), 10 μg/ml recombinant human insulin (MP Biomedicals) and 0.5 mM 3-isobutyl-1-methyl xanthine (Sigma-Aldrich, St. Louis, MO, USA)] for 48 hours. After the 48-hour induction, the hMSCs were washed with PBS and replaced with basal media. hMSCs were stained with Oil Red O 14 days post induction using standard cytochemistry techniques.
Results
Non-viral transfection efficiency and viability of hMSCs were similar for each transfection reagent tested (Fig. 1) . Naked pDNA alone was unable to transfect hMSCs and induce green fluorescent protein expression (GFP + ) (data not shown). For comparison, each transfection efficiency was normalized to N/P07 60 kDa branched PEI efficiency after 48 hours (2.9±0.6% of total cells GFP + ). Superfect, JetPEI and 60 kDa branched PEI produced similar transfection efficiencies after 24 hours (1.01±0.18, 0.58±0.05 and 0.37±0.15, of 48-hour N/P07 60 kDa branched PEI respectively) and 48 hours (0.65±0.49, 0.66±0.042 and 1.00± 0.20, of 48 hour N/P07 60 kDa branched PEI respectively) (Fig. 1a) . It is significant to note that the image-based method used to measure transfection efficiency was similar and slightly more conservative than the transfection efficiency measurement acquired using flow cytometry (Fig.  S1 ). Each transfection procedure decreased hMSC viability over 48 hours compared to untreated hMSCs (Fig. 1b) .
60 kDa branched PEI was explored in greater detail as a transfection reagent, since it is well-characterized, commercially available, low-cost and chemically modifiable. Increasing the N/P ratio from 0 to 7 in PEI/pDNA solutions resulted in higher hMSC transfection efficiencies. Four days post treatment, the highest transfection efficiencies were produced with N/P ratios of 5 (0.60±0.12 of 48-hour N/P07 60 kDa branched PEI) and 7 (0.74±0.12 of 48-hour N/P07 60 kDa branched PEI). Increasing the N/P ratio greater than 7 led to decreasing transfection efficiencies (Fig. 2a) . Increasing the N/P ratio from 0 to 12 had no significant effect on hMSC viability 24 hours post treatment. However, N/P ratios greater than 5 significantly decreased cell viability 48 hours post treatment (Fig. 2b) .
There was a clear trade-off between transfection efficiency and cell viability as the PEI/pDNA polyplex concentration was varied. Increasing polyplex concentrations produced higher hMSC transfection efficiencies and hMSCs treated with 8 μg/ml pDNA polyplexes (N/P07) produced the greatest transfection efficiency (3.28±0.41 of 48-hour N/P07 60 kDa branched PEI) (Fig. 2c) . However, 8 μg/ml pDNA polyplexes (N/P07) also reduced hMSC viability to 29.4±5.5% when compared to untreated cells. Doses of 1, 2 and 4 μg/ml pDNA polyplexes produced statistically equivalent transfection efficiencies and viability (Fig. 2c-d) . Although doses of 0.1 and 0.5 μg/ml PEI/pDNA polyplexes were less toxic to hMSCs, their transfection efficiencies were significantly lower than higher doses (Fig. 2c-d) .
The seeding density of hMSCs in culture and the hMSC passage number significantly influenced transfection via PEI/pDNA polyplexes. Cell seeding densities of 50-5000 hMSCs/cm 2 had the highest transfection efficiencies 24 hours post treatment (Fig. 3a) . Passage 7 (P7) hMSCs had the highest transfection efficiency 24 hours after treatment, while P6 hMSCs had the highest transfection efficiency 48 hours post treatment and both P6 and P7 hMSCs had higher transfection efficiencies than P8 hMSCs 96 hours post treatment (Fig. 3b) . To determine whether passagedependent differences in transfection efficiency may be due to differences in cell proliferation rate, we also measured the growth rate of each hMSC passage number. Passage 7 and 8 hMSCs had a slower growth rate 48 hours post seeding when compared to passage 6 hMSCs (p<0.05). However, Fig. 1 Effect of transfection reagents on transfection efficiency and hMSC viability. a Transfection efficiency of passage 6 hMSCs with pDNA complexed with JetPEI, Superfect, or 60 k branched PEI 1 and 2 days post transfection normalized to PEI transfection efficiency after 2 days. † Denotes significant difference between day 1 and day 2 transfection efficiencies. * Denotes significant increase compared to 60 kDa branched PEI (t-test, p <0.05). b Normalized viability of passage 6 hMSCs transfected with pDNA alone or complexed with 60 kDa branched PEI, Superfect, or JetPEI 48 hours post transfection. * Denotes significant difference with untreated hMSCs (t-test, p<0.05) the numbers of passage 6, 7 and 8 hMSCs in culture were not significantly different 96 hours post seeding (Fig. 3c) .
To further characterize the potential influence of the hMSC proliferation rate on transfection efficiency, we observed transfection in PEI/pDNA-containing hMSC cultures in which proliferation was inhibited by either a pharmacological inhibitor (mitomycin C) or gamma irradiation. Mitomycin C inhibited hMSC proliferation after 2, 4 and 6 hours of exposure when its concentration was ≥11.1 μg/ml. Greater concentrations of mitomycin C were cytotoxic, as indicated by a decrease in cell viability within 2 hours of mitomycin C treatment (Fig. S2 ) and we therefore used 11.1 μg/ml mitomycin C in transfection studies. Notably, this dose was similar to the 10 μg/ml mitomycin C used in a previous study to inhibit hMSC proliferation (McBeath et al. 2004 ). In a separate set of experiments, we used 6,000 rad gamma irradiation as an alternative mechanism to inhibit hMSC proliferation (Fig. 3d-e) and this dose was identical to the 6,000 rad dose used in a previous study to inhibit fibroblast division (Iuchi et al. 2006 ). Mitomycin C and gamma irradiation each slowed the rate of hMSC proliferation 24 hours and 96 hours post treatment but did not produce a decrease in cell number due to cell death (Fig. 3d) . Importantly, hMSCs treated with mitomycin C and gamma irradiation had transfection efficiencies significantly lower than hMSCs cultured in growth media 96 hours post treatment (Fig. 3e) .
Expression of CD105, a cell surface marker associated with multipotent hMSCs, was significantly decreased at particular timepoints after transfection treatment. CD105 expression was initially unaffected by transfection treatment, as measured by immunostaining 24 hours post treatment (Fig. 4a) . 48 hours post treatment CD105 expression Fig. 2 Characterization of PEI:pDNA polyplex-mediated hMSC transfection. a Normalized transfection efficiency of passage 6 hMSCs transfected with 60 kDa branched PEI:1 μg pDNA polyplexes formed at different N/P ratios. * Denotes significant difference compared to an N/P ratio of 0. † denotes significant difference in transfection efficiency between day 1 and 4 post transfection (t-test, p<0.05). b Viability of passage 6 hMSCs transfected with 60 kDa branched PEI:1 μg pDNA polyplexes formed at N/P ratios from 0 to 12 one and four days post transfection. * Denotes significant difference compared to an N/P ratio of 0 (t-test, p<0.05). c Normalized transfection efficiency of passage 6 hMSCs transfected with 0-8 μg 60 kDa branched PEI:pDNA polyplexes formed at an N/P ratio of 7. * Denotes significant difference compared to 1 μg pDNA (t-test, p<0.05). d Normalized viability of passage 6 hMSCs transfected with 60 kDa branched PEI:pDNA polyplexes with 0-8 μg pDNA. † Denotes significant difference with 1 μg pDNA. * Denotes significant difference with 0 μg pDNA (t-test, p< 0.05) was significantly reduced when treated with either 150 mM NaCl, 1 μg/ml pDNA, N/P07 PEI without plasmid DNA, or PEI/pDNA N/P03 compared to untreated hMSCs. In addition, the CD105 expression of transfected EGFP + hMSCs (treated with an N/P07) was significantly less than that of EGFP -hMSCs in the same cultures (Fig. 4b) . As expected, HUVECs had strong CD105 fluorescence (703±80 f.i.u.) and served as a positive control, while NIH3T3 cells had weak CD105 staining (42±30 f.i.u.) and served as a negative control (Fig. 4c) (Fonsatti et al. 2003) .
Transfection treatment and cell density may alter the hMSC differentiation potential down the osteogenic and adipogenic lineages. hMSCs that were not cultured in osteogenic induction medium did not show positive alizarin red staining or enhanced alkaline phosphatase staining, as expected. hMSCs cultured in osteogenic induction medium showed enhanced alkaline phosphatase staining and hMSCs treated with 1 μg pDNA complexed with 60 kDa PEI at an N/P ratio07 resulted in less alkaline phosphatase staining than untreated hMSCs, whether they were induced to differentiate at low or high cell densities (Fig. 5a-f) . Treatment with 1 μg pDNA complexed with 60 kDa PEI at an N/P ratio07 did not change the amount of alizarin red staining, regardless of the hMSC density (Fig. 5g-l) .
hMSCs that were never cultured in adipogenic induction media had no Oil Red O staining, as expected. hMSCs treated with 1 μg pDNA complexed with 60 kDa PEI at an N/P ratio07 showed positive Oil Red O staining, whether they were induced to differentiate at low or high cell densities. Untreated hMSCs did not stain positively for Oil Red O Fig. 3 Characterization of the cell culture parameters that affect transfection efficiency when hMSCs were treated with 1 μg pDNA complexed with 60 kDa PEI at an N/P ratio of 7. when they were induced to differentiate at low seeding densities but did stain positively for Oil Red O when they were induced to differentiate at high hMSC seeding density (Fig. 5m-r) . Taken together, these results suggest that treatment of hMSCs with 1 μg pDNA complexed with 60 kDa PEI at an N/P ratio07 influences their differentiation down the osteogenic and adipogenic lineages.
Discussion
Stem cell-based applications have design requirements that instruct the choice of an appropriate transfection technique. For example, tissue engineering (Palsson and Bhatia 2004) and drug screening (Eglen et al. 2008 ) approaches can each require billions of cells and often include multiple distinct cell types. Therefore, the cell source for many tissue engineering applications should be capable of proliferating in culture and differentiating into multiple somatic cell types. In view of this requirement, hMSCs were chosen as the cell source in this study, since they can be readily expanded in culture and can differentiate into multiple mesenchymal cell types. Toward that end, we examined the influence of a series of parameters on hMSC transfection efficiency and viability, including cell culture parameters (cell seeding density, cell passage number and cell division) and polyplex properties (polyplex N/P ratio and polyplex dose). Taken together, our results indicate that each of these parameters significantly influence hMSC transfection efficiency and viability and our initial analysis of hMSC markers and differentiation potential suggests that transfection treatment may also influence hMSC phenotype.
hMSC seeding density, proliferation rate and passage number had a significant impact on hMSC transfection efficiency and viability. The decrease in transfection efficiency at low hMSC seeding densities (Fig. 3a) could be attributed to the high dose of PEI:pDNA per number of cells, leading to a high proportional decrease in hMSC viability. The decrease in transfection efficiency at high cell seeding densities could be attributed in part to a decrease in hMSC division rate due to contact inhibition, which has been observed in previous studies (Lucarelli et al. 2003) . Importantly, hMSC proliferation also influenced transfection efficiency when probed more directly, as transfection efficiency was significantly reduced when hMSC proliferation was inhibited with the pharmacological inhibitor mitomycin C or gamma radiation (Fig. 3d,e) . It has been hypothesized that pDNA only diffuses into the nucleus when the nuclear membrane breaks down during mitosis (Brunner et al. 2000; Kunath et al. 2003; Tseng et al. 1999 ) and our current study provides supporting evidence that cell division may be necessary for hMSC transfection. Thus, we can hypothesize that in future large-scale transfections for tissue engineering applications, culture conditions that promote sustained high rates of hMSC division may provide optimal conditions for non-viral transfection. Notably, hMSC's have been shown to divide for over 10 passages using standard cell-culture techniques (Bruder et al. 1997 ) and work has begun on the robotic passaging of hMSCs for large-scale biotechnology applications (Thomas et al. 2007; Thomas et al. 2008 ). Automation of cell culture and real-time data processing of these cultures may ultimately enable optimization of hMSC division rates and, in turn, optimization of non-viral transfection efficiency.
The relatively high hMSC passage numbers used in this study were chosen based on the need for large numbers of hMSCs in tissue engineering and on previous studies that have demonstrated multipotency of hMSCs at a higher passage numbers. Bruder et al. serially passaged hMSCs to quantify growth rates and osteogenic potential and found no decrease in growth rate between P6 and P8. P6-P8 hMSCs were also able to upregulate their alkaline phosphatase expression greater than 10-fold when stimulated with osteogenic media (Bruder et al. 1997) . Therefore, in this manuscript hMSC division rates, transfection efficiency and differentiation potential were characterized at P6-P8. P7 and P8 hMSCs had a slightly lower cell number than P6 hMSCs after 48 hours in culture but by 96 hours there were no significant differences in the hMSC number when comparing the three passages (Fig. 3c) . These results are consistent with those in previous studies, in which P1, P4 and P7 hMSCs had similar growth rates for up to 10 days in culture (Bruder et al. 1997) . Although 4 days post seeding the passage number had no significant effect on hMSC proliferation, there was still a significant decrease in transfection efficiency between P6 and P8 hMSCs (Fig. 3b) . hMSC transfection efficiency was similarly shown to decrease with increased passage numbers in a previous study, in which a polyamidoamine dendrimer was used as a non-viral vector (Santos et al. 2009) . Further research will be necessary to characterize the mechanism dictating the decrease in transfection efficiency with increased hMSC passage numbers.
It is noteworthy that the PEI-mediated hMSC transfection efficiencies measured in this study are low (0-10%) but Fig. 5 Preliminary insights into differentiation potential of hMSCs after transfection. a-f Alkaline phosphatase-stained hMSCs that had been either never induced to differentiate, induced to differentiate, or transfected and induced to differentiate at low or high cell densities. g-l Alizarin redstained hMSCs that had been either never induced to differentiate, induced to differentiate, or transfected and induced to differentiate at low or high cell densities. m-r Oil Red Ostained hMSCs that had been either never induced to differentiate, induced to differentiate, or transfected and induced to differentiate at low or high cell densities. Scalebar denotes 20 μm consistent with the MSC transfection efficiencies observed in this study (Fig. 1) and previous studies using other non-viral vectors (Baksh et al. 2007; Clements et al. 2007a; Farrell et al. 2007) . Therefore, biotechnology applications that require higher transfection efficiencies may benefit from alternative techniques, such as electroporation or viral transduction. Seventy percent of hMSC transfection efficiencies have been reported using electroporation-based methods (Baksh et al. 2007 ) and viral vectors have induced greater than 80% hMSC transfection efficiencies (Love et al. 2007 ). However, high transfection efficiencies may not be necessary in all applications. For example, Park et al. encapsulated hMSCs with PEI/ pDNA polyplexes encoding bone morphogenetic protein-7 (BMP-7) in a chitosan-alginate hydrogel and demonstrated that the BMP-7 produced by a subset of hMSCs could induce mineralized tissue formation in the hydrogel matrix (Park et al. 2007 ). Other similar cell therapy approaches have used non-viral vectors to induce MSCs to produce glial cell linederived neurotrophic factor (Bolliet et al. 2008 ) and endostatin (Sun et al. 2009 ) at levels that are likely to have physiologic effects. These previous findings indicate that some tissue engineering applications may indeed benefit from non-viral gene delivery and that the parameters we explore in the current manuscript may be useful to enhance non-viral transfection efficiency in these applications.
Also consistent with previous reports, hMSC viability was significantly decreased by the various polycationic transfection reagents (Clements et al. 2007b; Gwak and Kim 2008; Saraf et al. 2008) (Fig. 1) . The mechanism of polycation toxicity is not well-understood (Wiethoff and Middaugh 2003) but cell signals associated with necrosis have been observed from liver (Tousignant et al. 2000) and muscle cells (Brazeau et al. 1998 ) after PEI-mediated transfection. As the different transfection reagents explored had similar transfection efficiencies, we decided to characterize PEI-mediated transfection in further detail for multiple reasons. First, PEI has been extensively studied and has a known chemical structure that is amenable to covalent modification. In addition, despite the widespread availability of many different polycationic transfection agents, only PEI has been considered economical and available for the literscale cultures needed for many biotechnology applications (Geisse 2009 ). We particularly chose 60 kDa branched PEI as a representative PEI, as branched PEIs of 10 kDa-1.6MDa have been used widely (Fischer et al. 1999; Godbey et al. 1999 ) and lower molecular weight PEIs within this range have been predominantly used in recent studies (Choosakoonkriang et al. 2003) . Taken together, these findings suggest that PEI may be a particularly suitable vector for stem cell-based applications and this reagent was therefore explored in detail in this study.
Experiments in which the formulation and dose of PEI:pDNA polyplexes were varied demonstrated a tradeoff between transfection efficiency and cell viability and revealed conditions that may be optimal for hMSC transfection (Fig. 2) . In general, the hMSC transfection efficiency was decreased when PEI exceeded a high enough concentration to achieve measurable transfection (Fig. 2a) and this phenomenon has been observed with other cell lines in previous studies (Boussif et al. 1995; Horbinski et al. 2001; Shin et al. 2005) . The mechanism behind this optimum range of polyplex N/P ratios can be attributed to previous observations that at low N/P ratios the PEI:pDNA polyplexes do not have a net positive charge on their surfaces and do not have small enough hydrodynamic radii to be endocytosed. Conversely, when the N/P ratio is too high PEI exerts toxic effects on the cells (Lungwitz et al. 2005) .
Increasing the dose of PEI/pDNA produced increasingly higher transfection efficiencies (Fig. 2c) . However, increasing the dose also led to increased hMSC toxicity (Fig. 2d) . One reason for this increase in toxicity could be unbound PEI in PEI:pDNA formulations, as described in previous studies (Clamme et al. 2003; Finsinger et al. 2000) and the unbound PEI produces increased cytotoxic effects (Boussif et al. 1995; Godbey et al. 2001) . Taken together, these findings indicate that the PEI/pDNA ratio and dose must be high enough to achieve measurable transfection but low enough to avoid toxic effects or interference with tissue formation by hMSCs.
Previous studies have defined hMSCs as SH2 + and CD105 + mononuclear cells derived from bone marrow, although it has been more recently shown that SH2 antibodies bind to an epitope on CD105 (Barry et al. 1999) . Therefore, for the purposes of our study, normal hMSC phenotype was defined by expression of CD105. Transfection treatment decreased CD105 expression (Fig. 4) , suggesting potential effects on hMSC phenotype. In addition, transfection treatment led to apparent differences in osteogenic and adipogenic induction of hMSCs. Specifically, transfection treatment led to a decrease in alkaline phosphatase staining after osteogenic induction at both low and high seeding densities and led to an increase in Oil Red O staining of hMSCs after adipogenic induction at a low seeding density (Fig. 5) . Taken together, these results offer preliminary evidence that transfection treatment influences the hMSC differentiation potential, perhaps by influencing the expression of canonical hMSC markers (e.g., CD105). Notably, previous studies with other cell lines have also shown that treatment with non-viral vectors can induce changes in gene expression (Akhtar and Benter 2007; Omidi et al. 2005; Omidi et al. 2003) and some of the genes explored in these previous studies are known regulators of hMSC differentiation. However, further studies will be needed to mechanistically delineate the effects of transfection treatment on hMSC phenotype.
Conclusion
Non-viral transfection efficiency and viability of hMSCs are dependent on both the cell-culture environment and the formulation of polycation/pDNA polyplexes. Cell-culture conditions that were previously demonstrated to promote hMSC multipotency also resulted in the greatest transfection efficiencies and cell division rate (i.e., P6-7 hMSCs, low seeding density, basal media). Alternatively, hMSC culture conditions that inhibited cell division also decreased transfection efficiency (i.e., culture conditions containing mitomycin C, hMSCs treated with gamma radiation, high hMSC cell seeding density). Preliminary experiments demonstrated that transfection treatment influenced the expression of the hMSC marker CD105 as well as the ability of hMSCs to differentiate down the osteogenic and adipogenic lineages. The relationships between cell-culture parameters and non-viral transfection efficiency explored here could be used to instruct future approaches for efficient non-viral transfection of hMSCs for tissue engineering applications and future studies will be needed to further delineate the mechanism governing effects of transfection treatment on hMSC phenotype.
